Corcept Therapeutics Incorporated. Forecast, price target & analysts
Corcept Therapeutics Incorporated. Target price 2026 - Analyst rating & recommendation
Corcept Therapeutics Incorporated. Classifications & Recommendation
Corcept Therapeutics Incorporated. Price Target
| Target Price | $165.75 |
| Price | $114.86 |
| Potential |
44.31%
register free of charge
|
| Number of Estimates | 8 |
|
8 Analysts have issued a price target Corcept Therapeutics Incorporated. 2027 .
The average Corcept Therapeutics Incorporated. target price is $165.75.
This is
44.31%
register free of charge
$173.25
50.84%
register free of charge
$50.50
56.03%
register free of charge
|
|
| A rating was issued by 12 analysts: 10 Analysts recommend Corcept Therapeutics Incorporated. to buy, 1 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Corcept Therapeutics Incorporated. stock has an average upside potential 2027 of
44.31%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 761.41 | 1,169.00 |
| 12.79% | 53.53% | |
| EBITDA Margin | 6.03% | 20.16% |
| 70.43% | 234.06% | |
| Net Margin | 13.09% | 19.40% |
| 37.44% | 48.23% |
7 Analysts have issued a sales forecast Corcept Therapeutics Incorporated. 2026 . The average Corcept Therapeutics Incorporated. sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Corcept Therapeutics Incorporated. EBITDA forecast 2026. The average Corcept Therapeutics Incorporated. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
8 Corcept Therapeutics Incorporated. Analysts have issued a net profit forecast 2026. The average Corcept Therapeutics Incorporated. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 0.83 | 2.10 |
| 33.06% | 153.01% | |
| P/E | 54.66 | |
| EV/Sales | 10.35 |
8 Analysts have issued a Corcept Therapeutics Incorporated. forecast for earnings per share. The average Corcept Therapeutics Incorporated. EPS is
This results in the following potential growth metrics and future valuations:
Corcept Therapeutics Incorporated....
Current Corcept Therapeutics Incorporated. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Jul 30 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jul 30 2026 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | Jul 30 2026 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Jul 29 2026 |
| Wolfe Research |
Locked
➜
Locked
|
Locked | Jul 27 2026 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | May 28 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | May 28 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Jul 30 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jul 30 2026 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Jul 30 2026 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Jul 29 2026 |
|
Locked
Wolfe Research:
Locked
➜
Locked
|
Jul 27 2026 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
May 28 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
May 28 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
